Psychosis Risk
Study register · detail Meta-Analyse · Psychosis Risk · 2026

Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.

Unclear GRADE High 0 citations
Samplek = 13 Studien
n = 7.515 Pat.
Durationunclear
EndpointPrevalence…
Blindingunklar
DesignMeta-Analyse
Key finding

Meta-analysis on the prevalence of schizophrenia-spectrum (20%) and bipolar disorders (5%) after cannabis-induced psychosis; no intervention assessment.

Summary

Systematic review + meta-analysis across k=13 studies (n=7.515) on cannabis-induced psychosis and subsequent diagnoses. 20% (95% CI: 15,8–29,5%) later developed schizophrenia-spectrum disorder, 5% (95% CI: 2,7–6,9%) bipolar disorder, 63% (95% CI: 26,8–90,5%) unspecified diagnosis. Patients had a 76% lower risk for bipolar disorder vs. schizophrenia-spectrum; unspecified diagnosis showed ARR=2,52 (95% CI: 1,03–6,15) vs. schizophrenia-spectrum alone.

P
PopulationPatients with cannabis-induced psychosis, pooled n=7.515
I
InterventionCannabis-induced psychosis (as exposure/baseline finding)
O
OutcomePooled prevalence: 20% (95% CI: 15,8–29,5%) later developed a schizophrenia-spectrum disorder; 5% (95% CI: 2,7–6,9%) a bipolar disorder; 63% (95% CI: 26,8–90,5%) an unspecified disorder; risk for bipolar disorder 76% lower than for schizophrenia-spectrum
Confidence in the evidence
High

The highest of four GRADE levels, the effect estimate is very reliable.

Quality profile
Sample size
Blinding
Effect size
Citations / year
Authors
Javed MS, El-Khoury R, Taha AA, Reagu SM
DOI 10.1186/s12888-025-07382-2
Design: Meta-Analyse
Share
Abstract
Background: Distinguishing cannabis-induced psychosis from primary psychiatric disorders is difficult and has significant clinical and prognostic implications. Current treatment approaches lack standardized guidelines, potentially leading to the development of schizophrenia spectrum and bipolar disorder. This study systematically reviews the literature and provides a pooled prevalence of later developing these disorders following a cannabis-induced psychosis diagnosis. Methods: We systematically reviewed Medline, Embase, Web of Science, Google Scholar, and PsychInfo for studies reporting on a group of patients with cannabis-induced psychosis and subsequent diagnoses of schizophrenia spectrum disorder, bipolar disorder, or both. The search was conducted until January 1, 2025. A modified version of the Newcastle-Ottawa scale was used to assess study quality. Random-effects meta-analyses were conducted to calculate pooled mean prevalence. Random-effects meta-regressions were used to identify predictors of higher prevalence. Results: Our strategy identified 13 studies eligible for inclusion with a total population size of 7,515 which reported a total of 16 outcomes of interest. Among cannabis induced psychosis patients, 20% (95% CI:15.8-29.5%) later received a schizophrenia spectrum diagnosis, 5% (95% CI:2.7-6.9%) bipolar and 63% (95% CI:26.8-90.5%) unspecified (both). Compared to individuals receiving a later schizophrenia spectrum disorder diagnosis, patients were 76% less likely to develop bipolar disorder. Later diagnosis of an unspecified disorder showed an approximate 3 folds higher risk with an ARR of 2.52 (95% CI: 1.03-6.15) compared to schizophrenia spectrum disorder alone. Conclusions: Approximately one in five patients diagnosed with cannabis-induced psychosis will develop schizophrenia spectrum disorder, while one in twenty will be later diagnosed with bipolar disorder.

The impediment to action advances action. — Marcus Aurelius